Ouabain is a member of one of the oldest class of pharmaceuticals used for treatment of heart failure,1 and its actions have been revisited since ouabain was identified in 1999 as an endogenous hormone.2 Ouabain is a well-known inhibitor of the -ATPase (sodium/potassium-adenosine triphosphatase; i.e., sodium pump) pathway, an energy-transducing ion pump which catalyzes active transport of sodium and potassium across the plasma membranes,3 and is highly conserved in all eukaryotic cells, including heart cells.
Extensive clinical observations demonstrated that in addition to its effects on ionic homeostasis, ouabain also stimulates myocardial metabolism. More specifically, ouabain increases lactic acid utilization by the myocardium, reduces lactic acid concentration in the blood of patients with heart disease, stimulates fatty acid utilization in the myocardium, and inhibits increased oxygen consumption induced by adrenaline.1 Studies over the past few years have clearly demonstrated that ouabain acts by binding on -ATPase, which is an important signal transducer.4 Binding of ouabain to -ATPase changes the interaction of the enzyme with neighboring membrane proteins, and induces the formation of multiple signaling modules, including increased production of reactive oxygen species (ROS). In cardiac myocytes, sodium pump inhibition is known to regulate cardiomyocyte metabolism, including the Ras-Rac-NAD(P)H oxidase cascade5 and redox potential.6 Regulation by ouabain of the sodium pump as an energy transducer thus became an important new line of investigation. Despite the importance of the effects of ouabain on myocardial metabolism, the precise mechanism of its action, particularly its action on the metabolic state of cardiac cells, is still poorly understood.
To evaluate the role of ouabain on the mitochondrial metabolic state, we have chosen a noninvasive spectroscopy method based on measuring the time- and spectrally resolved NAD(P)H endogenous fluorescence.7 This technique allows not only to determine changes in the fluorescence intensity, but also to separate individual NAD(P)H fluorescence components accordingly to their spectral characteristics and fluorescence lifetimes.8 Consequently, the applied approach allows us to evaluate changes in the cell’s metabolic oxidative mitochondrial redox state which correlate with redox potential.9,10 This procedure is tested as a perspective pharmaceutical procedure for monitoring the effect of drugs on the mitochondrial metabolism where ouabain is chosen as a model drug.
Pyruvate () and 3-β-hydroxybutyrate (BHB, ) were freshly prepared, while lactate () and acetoacetate (AcAc, or 1. ) were added to basic external solution from stock solution (, pH 7.2 for lactate, and 250 mM stock solution for AcAc). Rotenone () and 9,10-dinitrophenol (DNP, ) were added to cells in basic external solution for 5 to 25 min prior to recording. All chemicals were purchased from Sigma (Canada).
Animals and Cell Isolation
Female Sprague-Dawley rats (13 to 14 weeks old, Charles River, Canada) were studied. Left ventricular myocytes were isolated after retrograde perfusion of the heart with proteolytic enzymes.11 All procedures were performed in accordance with the National Institutes of Health (NIH) and Canadian Council on Animal Care (CCAC) guidelines, and evaluated by the local Comité Institutionnel des Bonnes Pratiques sur les Animaux en Recherche (CIBPAR), accredited by the CCAC. Myocytes were maintained in a storage solution at 4°C until used. Only cardiac myocytes showing clearly defined striations and edges were studied.
Time-Resolved Spectroscopy Measurements of NAD(P)H Fluorescence
NAD(P)H fluorescence was measured in isolated cardiac cells using a spectrally resolved time-correlated single photon counting (TCSPC) setup on an Axiovert 200 inverted microscope, as previously described.7,12 Picosecond laser diode BDL-375 (Becker&Hickl, Boston Electronics, USA) with emission at 375 nm was deployed at the 20 MHz repetition rate as an excitation source. All experiments were performed at room temperature.
The storage solution contained (in ): NaCl, 130.0; KCl, 5.4; , 1.4; , 0.4; creatine, 10.0; taurine, 20.0; glucose, 10.0; and HEPES, 10.0; titrated to pH 7.30 with NaOH. The basic external solution contained (in ): NaCl, 140.0; KCl, 5.4; , 2.0; , 1.0; glucose, 10.0; HEPES, 10.0; adjusted to pH 7.35 with NaOH. Ouabain was prepared freshly from powder and applied 10 min before use at concentrations from 10 to .
The data are reported as means standard error of the means (SEM). Data were collected from at least three different animals per experimental group, and compared by one-way analysis of variance (ANOVA); was considered statistically significant. Individual components of NAD(P)H fluorescence were estimated using principal component analysis (PCA),7 while the linear unmixing approach was applied to separate individual components in the recorded data, as previously reported13,14 Component amplitude for each resolved fluorescence component was calculated from the fluorescence decay kinetics using a monoexponential fitting procedure at the spectral channel with maximum intensity (450 nm). Fluorescence lifetime for each component was estimated in ns together with the component amplitude. Intensity for each component was calculated as .
Effect of Ouabain on the NAD(P)H Fluorescence Levels
In cardiac cells, principal endogenous indicators of the cellular oxidative metabolism are localized in mitochondria. The endogenous fluorescence generated after excitation with blue/ultraviolet light is mainly resulting from reduced mitochondrial NAD(P)H.15,16 This principal electron donor for electrochemical gradient necessary for ATP generation is used for noninvasive fluorescent probing of the metabolic state. These molecules exist in their free forms, or as cofactors in enzymes of inner mitochondrial membrane, and are involved in the mitochondrial respiratory chain and fatty acid oxidation. The time-resolved spectroscopy is an effective means to establish individual contribution of the two NAD(P)H forms, based on a spectral shift in the NADH spectrum upon binding to enzymes,17 and their distinct fluorescence lifetime. The short NAD(P)H fluorescence lifetime (0.4 ns), is accepted as an indicator of “free” NAD(P)H, while “protein-bound” NAD(P)H was described to have longer lifetimes (approximately 2 ns).18,19
The effect of oubain on the oxidative metabolic state of freshly isolated living cardiac myocytes was investigated by time-resolved spectroscopy of endogenous NAD(P)H fluorescence [see Fig. 1(a)], as described previously.7 A linear unmixing approach was used to separate individual NAD(P)H components; component 1 with fluorescence lifetime of around 1.8 ns corresponded to NAD(P)H in a more viscous environment, and this value is in agreement with published values of “bound” NAD(P)H in mitochondria20,21 [see resolved fluorescence decays in Fig. 1(b)]. The red-shifted component 2 with the fluorescence lifetime of 0.5 to 0.6 ns corresponded to NAD(P)H in a less viscous environment, and this value correlates with published values for “free” NAD(P)H in mitochondria20,21 [Fig. 1(c)]. The residual component 3 was also resolved [Fig. 1(d)], and with the maximum emission between 504 and 520 nm and fluorescence lifetime around 2 ns, it corresponded to flavin fluorescence.8,12 Ouabain had no significant effect on the fluorescence of component 3 at either concentration. Rising concentrations of ouabain affected mainly the integral intensity of component 2 [Fig. 1(c)] due to a drug-related effect on the amplitude of this component [Fig. 2(a), gray circles], which decreased with the dose of ouabain. This effect, observed in the absence of the ouabain-related action on fluorescence lifetimes of the two components [Fig. 2(b)], also had repercussions on decreasing intensity of the component, estimated as component amplitude fluorescence lifetime [Fig. 2(c)]. We noted no significant effect of ouabain on the resolved NAD(P)H component 1 [Fig. 2(a)–2(c), black squares].
Effect of Ouabain on Cell Oxidation Levels
Percentage of oxidized nucleotides is an important indicator of the state of the cell oxidation. To understand the implications of the modification of metabolic oxidative state by ouabain, we evaluated the effect of the drug on the percentage of oxidized nucleotides. Rotenone (), the inhibitor of Complex I in the respiratory chain,22,23 was used to put the cell in a fully reduced state at distinct concentrations of the glycoside, while DNP (), an uncoupling agent for ATP synthesis,16 was applied to induce a fully oxidized state [see an example of the actions of rotenone and DNP in the presence of ouabain at the component 1 and the component 2 in Fig. 3(a) and 3(b), respectively]. We calculated the percentage of oxidized nucleotides from the integral fluorescence intensity as [(fully reduced) − (control)]/[(fully reduced) − (fully oxidized)], where corresponds to the sum of integral fluorescence intensity for the two resolved NAD(P)H components. Using this approach, we demonstrated a clear decrease in this parameter from 70% in control conditions to about 35% at high concentrations of ouabain, with a half-response at [Fig. 3(c)]. Altogether, gathered data strongly indicate that ouabain induces a marked decrease in the cell’s oxidation levels.
redox potential is the driving force of oxidative phosphorylation, and its increase leads to a linear rise of maximal respiration rate in isolated heart mitochondria.24,25 This potential decreased in cardiac myocytes following ouabain action.6 These findings prompted us to evaluate changes in the cell metabolic oxidative redox state by determination of the mitochondrial ratio in cardiac cells. The ratio of the “free”/“bound” amplitude was proposed to correspond to the reduction/oxidation pair,9,10 and thus is considered an important indicator of modifications in the mitochondrial metabolic status. We evaluated the concentration-dependent effect of ouabain on the component amplitudes ratio of the resolved components, calculated as the component 2 to component 1 amplitude. Increasing concentrations of the glycoside decreased the component amplitudes ratio [Fig. 4(c), black squares]. This result is in accordance with a previously published observation that ouabain decreased the redox potential in cardiac myocytes.6 This result also confirms that ouabain decreases mitochondrial oxidation levels.
Effect of Ouabain in the Presence of Lactate and Pyruvate
Ouabain is known to increase lactic acid utilization by the myocardium and reduce lactic acid concentration in the blood of patients with heart disease.1 We have previously demonstrated the importance of the switch in the use of the lactate/pyruvate as an energy substrate as opposed to glucose alone on the cardiomyocyte function in both physiological and pathological situations.11,26 Therefore, we compared the effect of ouabain (100 and ) after application of lactate () in the presence of pyruvate (), both applied in concentrations found in the blood of studied animals,11 to promote the rise in the cytosolic NADH production. Despite little effect on the integral intensity or amplitude of the two resolved NAD(P)H components [Fig. 4(a) and 4(b)], and the observations confirming the primarily mitochondrial origin of the studied fluorescence, lactate and pyruvate stimulated the effect of ouabain on the component amplitudes ratio [Fig. 4(c), gray circles]. This finding points to a possible contribution of cytosolic NADH in the ouabain action.
Sensitivity of Mitochondrial NADH Production to Ouabain
To understand all aspects of the effect of ouabain on mitochondrial metabolic state, we also tested the role that the glycoside plays in the production of NADH by cardiomyocyte mitochondria. In cardiac tissue, NADH is produced by fatty acid oxidation from acetyl-CoA entering the Krebs cycle and this reaction depends on the BHB/AcAc ratio.27 As increasing the BHB/AcAc ratio from to favors the NADH production, we administered BHB () in a basic extracellular solution in the presence of different AcAc concentrations: 1.5 and ( and ratio, respectively) to vary NADH production. In accordance with decreased NADH concentration in cardiomyocyte mitochondria, the lowered ratio translated into a decrease of the integral fluorescence intensity in components 1 and 2 [Fig. 5(a)], due to the smaller amplitude of the two components [Fig. 5(b)], leading to a more important effect of BHB/AcAc on the component amplitudes ratio [Fig. 5(c)]. By inducing a lower increase in the amplitude of the resolved components, ouabain (100 nM) affected the capacity of BHB/AcAc to stimulate the NADH production. Based on the gathered data, maximal production of NADH was calculated from the integral intensity of both components as [control − (BHB:AcAc )]/[(BHB:AcAc ) − (BHB:AcAc )]. In this way, we estimated maximal production of NADH as 55.7% in control cells; in the presence of ouabain (), the NADH production increased to 75.5%, suggesting that ouabain increases the capacity of mitochondria to produce NADH.
In this study, we present a novel approach aimed to evaluate the effect of pharmaceutical drugs on the oxidative metabolic state of living cardiac cells by time-resolved spectroscopy of endogenous NAD(P)H fluorescence, using ouabain as a representative of a widely used class of pharmaceuticals. Our data revealed that the glycoside is capable of affecting cardiomyocyte metabolism. More precisely, 1. ouabain decreased the integral NAD(P)H intensity due to reduced amplitude of the NAD(P)H component 2. leading to a lowered component amplitudes ratio which indicates a change in metabolic oxidative state. 2. Cell oxidation levels, evaluated as percentage of oxidized NAD(P)H, decreased exponentially with rising concentrations of the cardiac glycoside. 3. Lactate/pyruvate, affecting the cytosolic NADH gradient, increased the effect of ouabain on the component amplitudes ratio. 4. Ouabain stimulated the mitochondrial NADH production. Overall, our data point to the fact that ouabain is acting by decreasing cell oxidation in cardiac myocytes.
Evaluation of the effects of pharmaceutical drugs on the mitochondrial metabolic state is crucial for understanding their potential role in affecting cellular energetics. Currently there is a lack of noninvasive techniques that would allow monitoring the effect of drugs on the cell metabolism directly in living cells and tissues. In recent years, advanced optical methods were developed for detection of mitochondrial oxidative state in living systems. Latest developments in time-resolved spectroscopy include the multi-photon excited time-resolved fluorescence, as well as spectrally resolved time-correlated single photon counting of various endogenously fluorescing molecules.8,28 Fluorescence lifetime imaging uses tissue autofluorescence (AF) to characterize endogenous fluorophores [NAD(P)H and flavins] which reflect redox processes in the mitochondrial matrix, and thus allow monitoring of their important role in the cell metabolism. Time-resolved spectroscopy measurements29,30 of NAD(P)H and flavins were shown to be suitable for scoring the metabolic state of various cells, and serve as optical biomarkers in cardiomyocytes, but also in other cells including cancer cells and precancerous lesions.8 Additional improvements in the detection by AF can be obtained by separating individual AF components using time-resolved and/or spectral techniques.13,14,31 In this study, we applied time-resolved spectroscopy of endogenous NAD(P)H fluorescence to test a perspective procedure for evaluating the effect of pharmaceutical drugs on the mitochondrial metabolism. Ouabain was chosen as a model drug.
Ouabain was shown to affect cardiovascular function,32 as lowering of regional myocardial blood flow altered the drug binding properties and participated in the reduction of cardiac glycoside binding after reperfusion of ischemia myocardium.33 Other researchers demonstrated that ouabain protects rat hearts against ischemia-reperfusion injury via a pathway involving ROS.34 Ouabain was also proposed to regulate mitochondrial metabolism through -ATPase-mediated signal transmission;3 however, there is rather confusing information on the role of cardiac glycosides in the modulation of the mitochondrial metabolism. Our data confirm the capacity of ouabain to affect mitochondrial metabolic state by acting on the amount of NAD(P)H molecules in cardiac cells. Lack of significant effect of the ouabain on the fluorescence lifetimes of NAD(P)H fluorescence indicates that this effect is most likely due to regulation of NAD(P)H production and utilization, without affecting molecular environment.
Our data point to the fact that the effect of ouabain is affected by modification in the energy substrates, particularly lactate/pyruvate versus glucose. We have previously demonstrated11 that a switch in the use of these substrates is highly important in certain physiological conditions, such as physiological and pathological pregnancy, which are also characterized by increased levels of endogenous ouabain.35 This result can be of importance also in other pathological conditions as the sodium pump is regulated in conditions such as hyperglycemia associated with diabetes,36 and is linked to mediation of the glucose uptake and/or lactate production.
-ATPase was shown to interact with multiple signaling proteins to transmit ouabain signals,3,37 and several intracellular pathways are known to be implicated in this transmission; namely, ouabain was shown to affect mitochondrial NAD(P)H and ROS generation.5 Recently, oxidative signaling based on NAD(P)H oxidase and superoxide was demonstrated to play an important role in the pump inhibition.38 These authors proposed that regulation of the pump is governed by redox signaling via activation of colocalized NAD(P)H oxidase. Oxidative regulation of the pump function is thought to be of pathophysiological importance, particularly in the heart failure. We previously demonstrated that oxidative stress has a repercussion of lowering of the NAD(P)H fluorescence via stimulation of NAD(P)H-dependent pathways (see supplement in Ref. 26). Consequently, we propose the investigation of the ouabain effect on NAD(P)H-dependent pathways should be the target of future studies. At the same time, failure of ouabain to affect the third residual flavin component indicates that its action is not likely to involve modification in the flavoprotein complexes, but rather a drug-related action on the amount of available NAD(P)H molecules in the cell. Overall, our data demonstrate that, in cardiomyocytes, ouabain exercises a balanced effect on decreasing the cell oxidation levels and increasing the NADH production.
Our study uncovers the role of ouabain in the regulation of the metabolic oxidative state, and presents a perspective approach for pharmaceutical testing of drug-related effects on the mitochondrial metabolism by means of time-resolved spectroscopy of endogenous NAD(P)H fluorescence. Gathered data point to the fact that ouabain provokes a change of the metabolic oxidative state towards lowering of the cellular oxidation levels. Ouabain decreases the percentage of oxidized nucleotides while stimulating the NADH production in mitochondria, pointing to a carefully balanced effect of the drug on cellular energetics. To our knowledge, this study is the first to examine the effect of ouabain on the oxidative metabolic state in living cardiac myocytes by evaluating the NAD(P)H fluorescence by lifetime spectroscopy.
Authors acknowledge support from the Heart and Stroke Foundation of Quebec, Integrated Initiative of European Laser Infrastructures LaserLab Europe II (EC’s Seventh Framework Programme FP7/2007-2013 under grant agreement No. 228334), and the Research grant agency of the Ministry of Education, Science, Research and Sport of the Slovak Republic VEGA No. 1/0296/11. F. Elzwiei is a recipient of the Libyan Ministry of Superior Studies. The authors would like to thank V. Bassien-Capsa for help with cell preparation, and C. Des Rosiers for the generous gift of AcAc.
H. Furstenwerth, “Ouabain—the insulin of the heart,” Int. J. Clin. Pract. 64(12), 1591–1594 (2010).1368-5031http://dx.doi.org/10.1111/j.1742-1241.2010.02395.xGoogle Scholar
A. Y. BagrovJ. I. ShapiroO. V. Fedorova, “Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets,” Pharmacol. Rev. 61(1), 9–38 (2009).PAREAQ0031-6997http://dx.doi.org/10.1124/pr.108.000711Google Scholar
Z. Xieet al., “Intracellular reactive oxygen species mediate the linkage of -ATPase to hypertrophy and its marker genes in cardiac myocytes,” J. Biol. Chem. 274(27), 19323–19328 (1999).JBCHA30021-9258http://dx.doi.org/10.1074/jbc.274.27.19323Google Scholar
T. LiuD. A. BrownB. O'Rourke, “Role of mitochondrial dysfunction in cardiac glycoside toxicity,” J. Mol. Cell. Cardiol. 49(5), 728–736 (2010).JMCDAY0022-2828http://dx.doi.org/10.1016/j.yjmcc.2010.06.012Google Scholar
D. Chorvat Jr.et al., “Rejection of transplanted hearts in patients evaluated by the component analysis of multi-wavelength NAD(P)H fluorescence lifetime spectroscopy,” J. Biophotonics 3(10–11), 646–652 (2010).JBOIBX1864-063Xhttp://dx.doi.org/10.1002/jbio.201000040Google Scholar
D. Chorvat Jr.A. Chorvatova, “Multi-wavelength fluorescence lifetime spectroscopy: a new approach to the study of endogenous fluorescence in living cells and tissues,” Laser Phys. Lett. 6(3), 175–193 (2009).1612-2011http://dx.doi.org/10.1002/lapl.v6:3Google Scholar
D. K. Birdet al., “Metabolic mapping of MCF10A human breast cells via multiphoton fluorescence lifetime imaging of the coenzyme NADH,” Cancer Res. 65(19), 8766–8773 (2005).CNREA80008-5472http://dx.doi.org/10.1158/0008-5472.CAN-04-3922Google Scholar
R. Niesneret al., “Noniterative biexponential fluorescence lifetime imaging in the investigation of cellular metabolism by means of NAD(P)H autofluorescence,” Chemphyschem 5(8), 1141–1149 (2004).CPCHFT1439-4235http://dx.doi.org/10.1002/(ISSN)1439-7641Google Scholar
V. Bassien-Capsaet al., “Structural, functional and metabolic remodeling of rat left ventricular myocytes in normal and in sodium-supplemented pregnancy,” Cardiovasc. Res. 69(2), 423–431 (2006).CVREAU0008-6363http://dx.doi.org/10.1016/j.cardiores.2005.10.017Google Scholar
D. Chorvat Jr.A. Chorvatova, “Spectrally resolved time-correlated single photon counting: a novel approach for characterization of endogenous fluorescence in isolated cardiac myocytes,” Eur. Biophys. 36(1), 73–83 (2006).EBJOE80175-7571http://dx.doi.org/10.1007/s00249-006-0104-4Google Scholar
D. Chorvat Jr.et al., “Spectral unmixing of flavin autofluorescence components in cardiac myocytes,” Biophys. J. 89(6), L55–L57 (2005).BIOJAU0006-3495http://dx.doi.org/10.1529/biophysj.105.073866Google Scholar
D. Chorvat Jr.et al., “Application of spectral unmixing in multi-wavelength time-resolved spectroscopy,” Proc. SPIE 6771, 677105 (2007).PSISDG0277-786Xhttp://dx.doi.org/10.1117/12.732880Google Scholar
B. Chance, “Pyridine nucleotide as an indicator of the oxygen requirements for energy-linked functions of mitochondria,” Circ. Res. 38(5 Suppl. 1), I31–I38 (1976).CIRUAL0009-7330Google Scholar
D. N. RomashkoE. MarbanB. O'Rourke, “Subcellular metabolic transients and mitochondrial redox waves in heart cells,” Proc. Natl. Acad. Sci. USA 95(4), 1618–1623 (1998).1091-6490http://dx.doi.org/10.1073/pnas.95.4.1618Google Scholar
B. ChanceJ. B. Neilands, “Studies on lactic dehydrogenase of heart, II. a compound of lactic dehydrogenase and reduced pyridine nucleotide,” J. Biol. Chem. 199(1), 383–387 (1952).JBCHA30021-9258Google Scholar
D. M. JamesonV. ThomasD. M. Zhou, “Time-resolved fluorescence studies on NADH bound to mitochondrial malate dehydrogenase,” Biochim. Biophys. Acta 994(2), 187–190 (1989).BBACAQ0006-3002http://dx.doi.org/10.1016/0167-4838(89)90159-3Google Scholar
J. R. Lakowiczet al., “Fluorescence lifetime imaging of free and protein-bound NADH,” Proc. Natl. Acad. Sci. USA 89(4), 1271–1275 (1992).1091-6490http://dx.doi.org/10.1073/pnas.89.4.1271Google Scholar
K. Blinovaet al., “Distribution of mitochondrial NADH fluorescence lifetimes: steady-state kinetics of matrix NADH interactions,” Biochemistry 44(7), 2585–2594 (2005).BICHAW0006-2960http://dx.doi.org/10.1021/bi0485124Google Scholar
H. D. Vishwasraoet al., “Conformational dependence of intracellular NADH on metabolic state revealed by associated fluorescence anisotropy,” J. Biol. Chem. 280(26), 25119–25126 (2005).JBCHA30021-9258http://dx.doi.org/10.1074/jbc.M502475200Google Scholar
K. J. DaviesJ. H. Doroshow, “Redox cycling of anthracyclines by cardiac mitochondria, I. anthracycline radical formation by NADH dehydrogenase,” J. Biol. Chem. 261(7), 3060–3067 (1986).JBCHA30021-9258Google Scholar
R. Moreno-Sanchez, “Regulation of oxidative phosphorylation in mitochondria by external free Ca2+ concentrations,” J. Biol. Chem. 260(7), 4028–4034 (1985).JBCHA30021-9258Google Scholar
V. K. MoothaA. E. AraiR. S. Balaban, “Maximum oxidative phosphorylation capacity of the mammalian heart,” Am. J. Physiol. 272(2 Pt. 2), H769–H775 (1997).AJPHAP0002-9513Google Scholar
V. Bassien-Capsaet al., “Metabolic remodelling of cardiac myocytes during pregnancy: the role of mineralocorticoids,” Can. J. Cardiol. 27(6), 834–842 (2011).CJCAEX0828-282Xhttp://dx.doi.org/10.1016/j.cjca.2011.05.009Google Scholar
L. H. OpieP. Owen, “Effects of increased mechanical work by isolated perfused rat heart during production or uptake of ketone bodies. Assessment of mitochondrial oxidized to reduced free nicotinamide-adenine dinucleotide ratios and oxaloacetate concentrations,” Biochem. J. 148(3), 403–415 (1975).BIJOAK0264-6021Google Scholar
W. Becker, Advanced Time-Correlated Single Photon Counting Techniques, Springer, New York (2005).Google Scholar
D. V. O'ConnorD. Phillips, Time-Correlated Single Photon Counting, Academic Press, London (1984).Google Scholar
J. R. Lakowicz, J. R. Principles of Fluorescence Spectroscopy Introducing the Phase-Modulation Methods, Springer, New York (1999).Google Scholar
T. ZimmermannJ. RietdorfR. Pepperkok, “Spectral imaging and its applications in live cell microscopy,” FEBS Lett. 546(1), 87–92 (2003).FEBLAL0014-5793http://dx.doi.org/10.1016/S0014-5793(03)00521-0Google Scholar
G. A. BellerJ. ConroyT. W. Smith, “Ischemia-induced alterations in myocardial ()-ATPase and cardiac glycoside binding,” J. Clin. Invest. 57(2), 341–350 (1976).JCINAO0021-9738http://dx.doi.org/10.1172/JCI108285Google Scholar
P. Pasdoiset al., “Ouabain protects rat hearts against ischemia-reperfusion injury via pathway involving src kinase, mitoKATP, and ROS,” Am. J. Physiol. 292(3), H1470–H1478 (2007).AJPHAP0002-9513http://dx.doi.org/10.1152/ajpheart.00877.2006Google Scholar
D. A. Lopatinet al., “Circulating bufodienolide and cardenolide sodium pump inhibitors in preeclampsia,” J. Hypertens. 17(8), 1179–1187 (1999).JOHYD30263-6352http://dx.doi.org/10.1097/00004872-199917080-00018Google Scholar
P. A. Hansenet al., “Alloxan-induced diabetes reduces sarcolemmal pump function in rabbit ventricular myocytes,” Am. J. Physiol. 292(3), C1070–C1077 (2006).AJPHAP0002-9513http://dx.doi.org/10.1152/ajpcell.00288.2006Google Scholar
Z. XieA. Askari, “-ATPase as a signal transducer,” Eur. J. Biochem. 269(10), 2434–2439 (2002).EJBCAI0014-2956http://dx.doi.org/10.1046/j.1432-1033.2002.02910.xGoogle Scholar